- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 15.01. | Hypha Labs, Inc. - 10-K, Annual Report | 2 | SEC Filings | ||
| 30.12.25 | Hypha Labs, Inc. - NT 10-K, Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 | - | SEC Filings | ||
| 01.10.25 | Hypha Labs, Tryptomics enter phase II of mushroom tech partnership | 1 | Investing.com | ||
| 01.10.25 | Hypha Labs, Inc.: Hypha Labs and Tryptomics Launch Phase II of Strategic Partnership, Pairing Patented Mushroom Accelerator with World-Class Internal Quality Control & Fungal Genomics | 458 | ACCESS Newswire | LAS VEGAS, NV / ACCESS Newswire / October 1, 2025 / Hypha Labs, Inc. (OTCQB:FUNI), a biotechnology company pioneering the development of functional mushroom technologies, today announced the official... ► Artikel lesen | |
| 29.09.25 | Hypha Labs to build commercial-scale mushroom accelerator | 1 | Investing.com | ||
| HYPHA LABS Aktie jetzt für 0€ handeln | |||||
| 29.09.25 | Hypha Labs, Inc.: Hypha Labs and Automated Technical Services Enter into Agreement to Scale its Mushroom Accelerator Technology for Commercial Nutraceutical Manufacturing | 242 | ACCESS Newswire | LAS VEGAS, NV / ACCESS Newswire / September 29, 2025 / Hypha Labs, Inc. (OTCQB:FUNI), a biotechnology company pioneering the development of functional mushroom technologies, announced today that it... ► Artikel lesen | |
| 21.08.25 | Hypha Labs, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 14.08.25 | Hypha Labs, Inc. - NT 10-Q, Notification of inability to timely file Form 10-Q or 10-QSB | 1 | SEC Filings | ||
| 11.08.25 | Hypha Labs, Inc.: Hypha Labs Expands List of Functional Mushrooms Able to be Produced in its Revolutionary Mushroom Accelerator | 252 | ACCESS Newswire | Simple, In-Home Eight Day Cycle Generates Significant Yields of The World's Most Popular Mushroom Strains LAS VEGAS, NV / ACCESS Newswire / August 11, 2025 / Hypha Labs, Inc. (OTCQB:FUNI), an A.I. powered... ► Artikel lesen | |
| 28.07.25 | Hypha Labs, Inc.: Hypha Labs Provides Shareholder Update | 785 | ACCESS Newswire | LAS VEGAS, NEVADA / ACCESS Newswire / July 28, 2025 / Hypha Labs, Inc. (OTCQB:FUNI), an Artificial Intelligence (AI) powered pioneer in functional mushroom sciences and the creator of the MicroPearls... ► Artikel lesen | |
| 10.06.25 | Hypha Labs, Inc.: Hypha Labs Files New Patent Application for Its Suite of Artificial Intelligence Techniques for Its Mushroom Accelerator | 475 | ACCESS Newswire | LAS VEGAS, NV / ACCESS Newswire / June 10, 2025 / Hypha Labs, Inc. (OTCQB:FUNI), an Artificial Intelligence (AI) powered pioneer in functional mushroom sciences and the creator of the MicroPearls suite... ► Artikel lesen | |
| 13.05.25 | Hypha Labs, Inc.: Hypha Labs Files Multiple Additional Patents for its Ground Breaking Mushroom Accelerator | 389 | ACCESS Newswire | LAS VEGAS, NV / ACCESS Newswire / May 13, 2025 / Hypha Labs, Inc. (OTCQB:FUNI), a pioneer in functional mushroom sciences and the creator of the MicroPearls suite of products, is pleased to announce... ► Artikel lesen | |
| 01.05.25 | Hypha Labs, Inc.: Hypha Labs Acquires State-of-the-Art HPLC Analytic Machine and Partners with Lucidity Systems for Advanced Autosampler Upgrade | 599 | ACCESS Newswire | LAS VEGAS, NV / ACCESS Newswire / May 1, 2025 / Hypha Labs, Inc. (OTCQB:FUNI), a pioneer in functional mushroom sciences and the creator of the MicroPearls suite of products, is pleased to announce... ► Artikel lesen | |
| 09.04.25 | Hypha Labs, Inc.: New Mexico Governor Signs Bill Allowing for Psilocybin Use | 358 | ACCESS Newswire | 'Medical Psilocybin Act' Provides Legal Access to Citizens for the First Time LAS VEGAS, NV / ACCESS Newswire / April 9, 2025 / Hypha Labs, Inc. (OTCQB:FUNI), a pioneer in functional mushroom sciences... ► Artikel lesen | |
| 17.03.25 | Hypha Labs, Inc.: Hypha Laboratories Retains Stockhouse for International Awareness Campaign | 354 | ACCESS Newswire | Venerable, Popular Destination to Introduce Hypha Labs to Canadian and U.S. Investors LAS VEGAS, NV / ACCESS Newswire / March 17, 2025 / Hypha Labs, Inc. (OTCQB:FUNI), a pioneer in functional mushroom... ► Artikel lesen | |
| 30.01.25 | Hypha Labs, Inc.: Hypha Laboratories Reports Significant Breakthrough for MicroPearls Yields | 393 | ACCESS Newswire | In-Home Consumer Harvests Increase Exponentially After Research Discovery at Hypha Laboratories LAS VEGAS, NEVADA / ACCESS Newswire / January 30, 2025 / Hypha Labs, Inc. (OTCQB:FUNI), a pioneer in functional... ► Artikel lesen |
16 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SUMMIT THERAPEUTICS | 15,400 | 0,00 % | Summit Therapeutics Inc. - 8-K, Current Report | ||
| COGENT BIOSCIENCES | 37,650 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Breakthrough Therapy Designation for Bezuclastinib in Combination with Sunitinib for Patients with Gastrointestinal Stromal Tumors (GIST) | - Cogent will submit the PEAK New Drug Application (NDA) under previously announced RTOR designation; on track to complete NDA submission in April 2026 WALTHAM, Mass. and BOULDER, Colo., Jan. 26... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 69,98 | 0,00 % | Apogee Therapeutics: Empfehlung liefert +129% in 6 Monaten | Im Juli letzten Jahres präsentierten wir im Rahmen unserer Berichterstattung und innerhalb unserer erfolgreichen Community die Aktie von Apogee Therapeutics als heißen Kauftipp. Grundlage war eine ausgeprägte... ► Artikel lesen | |
| IMMUNOVANT | 26,450 | +1,50 % | Immunovant Inc.: Immunovant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026 | ||
| ALUMIS | 26,840 | 0,00 % | Alumis Inc.: Alumis Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares | SOUTH SAN FRANCISCO, Calif., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing next-generation targeted therapies for patients with... ► Artikel lesen | |
| DAY ONE BIOPHARMACEUTICALS | 11,160 | 0,00 % | Day One Biopharmaceuticals, Inc.: Day One Announces Preliminary 2025 OJEMDA Net Product Revenue And Provides 2026 Net Product Revenue Guidance | Preliminary 2025 net product revenue of $155.4 million, representing 172% year-over-year growth; OJEMDA 2026 U.S. net product revenue projected to be $225 - $250 million Company to present on corporate... ► Artikel lesen | |
| DYNE THERAPEUTICS | 17,880 | +1,02 % | Keros Therapeutics vs. Dyne: Which DMD Biotech Has More Upside? | ||
| STRUCTURE THERAPEUTICS | 87,15 | -2,13 % | Weight Loss Drugs Market Is Crowded But Structure Therapeutics CEO Has A Strategy For It | ||
| IMMUNOME | 25,070 | 0,00 % | Immunome: Guggenheim bestätigt Kaufempfehlung nach 400-Millionen-Dollar-Finanzierung | ||
| ERASCA | 10,310 | +1,78 % | Erasca, Inc. - 8-K, Current Report | ||
| AVIDITY BIOSCIENCES | 72,56 | +0,14 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights | Announced Novartis agreement to acquire Avidity for total equity value of approximately $12 billion; Avidity expects to separate its early-stage precision cardiology... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 314,68 | +1,54 % | Piper Sandler raises Praxis Precision Medicines stock price target to $1,200 | ||
| RECURSION PHARMACEUTICALS | 4,320 | 0,00 % | Recursion Pharmaceuticals, Inc.: Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks | REC-4881 (4 mg QD) achieved rapid clinical activity, with 75% of evaluable patients showing reductions in total polyp burden and a 43% median reduction after 12 weeks of treatment (n=12)After 12 weeks... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 25,730 | +1,10 % | Arcutis, Kowa part ways on US marketing partnership for Zoryve | ||
| MINERALYS THERAPEUTICS | 32,090 | -0,77 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics' Phase 3 Launch-HTN Trial of Lorundrostat Recognized in Inaugural Journal of the American Medical Association (JAMA) "Research of the Year" Roundup | - Launch-HTN, the largest trial of an aldosterone synthase inhibitor conducted among participants with uncontrolled or treatment-resistant hypertension, was one of nine studies selected as most impactful... ► Artikel lesen |
HYPHA LABS INC gehört der Branche Biotechnologie an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu HYPHA LABS INC finden Sie auf Wallstreet Online.